mRNA Expression in Lymphocytes of Glaucoma Patients
Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients
調査の概要
詳細な説明
Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The glaucoma patients will be divided into four groups: (1) high tension glaucoma, (2) normal tension glaucoma, (3) pseudoexfoliation glaucoma, and (4) juvenile glaucoma. Healthy subjects are separated into two age groups. Vasospastic propensity will be assessed with a questionnaire: patients and subjects answering yes to the questions: "do you have always cold hands, even during summer time?" and "do other people tell you that you have cold hands?" will be classified as vasospastic, and as normals if they deny a history of cold hands. Blood will be drawn from an arm vein, lymphocytes will be isolated and mRNA of following genes will be assessed in these lymphocytes:
Nuclear proteins: NF-kappa B, XPGC, P53, XIAP; Multi-drug resistance proteins: ABC 1, ABC 8, MDR 3; Adhesion protein: ICAM 1; Blood brain barrier breakdown protein: P2Y; Energy metabolism proteins: Adrenodoxin, Adrenodoxin-reductase, Cytochrome p450, Cytochrome-reductase, Alcohol-dehydrogenase; Tissue remodeling proteins: MMP 9, MMP 8, MMP 14, TIMP 1, TIMP 2, TIMP 3, TIMP 4.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
BS
-
Basel、BS、スイス、4031
- University Hospital Basel, Eye Clinic
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Glaucoma patients
- diagnosis of chronic glaucoma with typical glaucomatous disc and visual field damage
- a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment HTG)
- a present or past diurnal tension curve with an average intraocular pressure below 21 mmHg without treatment (NTG)
- a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment and signs of pseudoexfoliation in the anterior segment (PEX)
- a juvenile-onset open-angle glaucoma with a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment (Juvenile Glaucoma)
Healthy subjects
- no history of ocular disease
- no history of systemic disease
- no history of alcohol/drug abuse
- normal blood pressure (100-140 / 60-90 mmHg)
- best corrected visual acuity above 20/25 in both eyes
- no pathological findings upon a slit-lamp examination and indirect fundoscopy
- IOP < 20 mmHg in both eyes
Exclusion Criteria:
- Ametropia > 3 dpt
- Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
- Pigmentary dispersion
- any abnormality which in the physician's view would prevent reliable applanation tonometry
- History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis
- History of ocular trauma or intraocular surgery within the past 6 months
- History of infection or inflammation within the past 3 months
- History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment
- Need for any concomitant medications that may interfere with the evaluation of ocular blood flow
- significant history and/or active alcohol or drug abuse
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：ケースコントロール
- 時間の展望：見込みのある
コホートと介入
グループ/コホート |
|---|
|
1-HTG
high tension glaucoma highest IOP > 21 mmHg
|
|
2-NTG
normal tension glaucoma highest measured IOP < 21 mmHg
|
|
3-PEX
pseudoexfoliation glaucoma PEX material visible
|
|
4-Juvenile
juvenile glaucoma
|
|
5-Control1
healthy subjects (age group 1)
|
|
6-Control2
healthy subjects (age group 2)
|
協力者と研究者
捜査官
- スタディディレクター：Selim Orgül, MD、University Hospital, Basel, Switzerland
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。